…pathways. Proarrhythmic events occur in 5% to 10% of patients receiving antiarrhythmic agents, and this risk is amplified in the presence of heart failure. Clinical…

…on dialysis, where DOACs lack documentation or have only weak evidence. Venous thromboembolism when a DOAC cannot be used (interactions, cost, adherence, pregnancy after the…

…generally not recommended. If deemed necessary after careful individual benefit risk assessment by the prescribing physician: Initial dose : 60 mg single loading dose. Maintenance dose…

…despite maximally tolerated therapy. It is a prodrug activated predominantly in the liver by very long chain acyl CoA synthetase 1. This activating enzyme is…

…was performed; the type of revascularization; stent related risk; whether long term oral anticoagulation is required; tolerance of treatment during the initial months. Patients with…

…Diagnostics Electrocardiography and Electrophysiology Electrocardiographic evaluation of patients receiving digoxin reveals specific electrophysiologic profiles. Digoxin's autonomic actions largely slow the sinus node discharge rate…

…event while receiving maximally tolerated statin therapy, an LDL C goal below 1.0 mmol/L (<40 mg/dL) may be considered. The cited recommendations…

…one ASCVD risk equivalent who were receiving statins, inclisiran produced a further reduction in LDL C of approximately 50%. The effect was consistent in patients…

…naïve patients unlikely to achieve the LDL C goal with statin therapy alone, initiation of high intensity statin plus ezetimibe during hospitalization should be considered…

…receiving maximally tolerated statin therapy, an LDL C goal below 1.0 mmol/L (<40 mg/dL) may be considered in the circumstances specified by…